These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 4744972

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].
    Giachino G, Giacchino F, Jeantet A, Del Piano A, Garetto A, Pellerey M, Piccoli G.
    Minerva Med; 1985 Mar 10; 76(9-10):407-14. PubMed ID: 2984605
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Controlled study of renal osteodystrophy in patients undergoing dialysis. Improved response to continuous ambulatory peritoneal dialysis compared with hemodialysis.
    Shusterman NH, Wasserstein AG, Morrison G, Audet P, Fallon MD, Kaplan F.
    Am J Med; 1987 Jun 10; 82(6):1148-56. PubMed ID: 3605132
    [Abstract] [Full Text] [Related]

  • 8. Can renal bone disease be prevented?
    Shaldon S.
    Proc Eur Dial Transplant Assoc; 1973 Jun 10; 10(0):91-123. PubMed ID: 4808119
    [No Abstract] [Full Text] [Related]

  • 9. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP.
    Clin Nephrol; 1996 Feb 10; 45(2):111-9. PubMed ID: 8846523
    [Abstract] [Full Text] [Related]

  • 10. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG, Goldstein DA, Malluche HH.
    Kidney Int; 1980 Oct 10; 18(4):409-18. PubMed ID: 7014981
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
    Ogata H, Koiwa F, Shishido K, Kinugasa E.
    Ther Apher Dial; 2005 Feb 10; 9(1):11-5. PubMed ID: 15828900
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
    D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME.
    Kidney Int Suppl; 2003 Jun 10; (85):S73-8. PubMed ID: 12753271
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The radiographic spectrum of renal osteodystrophy.
    Molpus WM, Pritchard RS, Walker CW, Fitzrandolph RL.
    Am Fam Physician; 1991 Jan 10; 43(1):151-8. PubMed ID: 1986484
    [Abstract] [Full Text] [Related]

  • 19. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L, Daugaard H, Nielsen PK, Jensen LT, Egsmose C, Olgaard K.
    Nephron; 1996 Jan 10; 74(1):89-103. PubMed ID: 8883025
    [Abstract] [Full Text] [Related]

  • 20. [Sevelamer hydrochloride and K/DOQI guidelines].
    Yumita S.
    Clin Calcium; 2005 Sep 10; 15 Suppl 1():180-4. PubMed ID: 16279022
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.